ReviewApplied microbiology and biotechnology2012
Recent advances in technology supporting biopharmaceutical production from mammalian cells.
Review in Applied microbiology and biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 205 citations in OpenAlex.
- Purification, biochemical characterization and fibrinolytic potential of proteases produced by bacteria of the genus Bacillus: a systematic literature review.Archives of microbiology · 2022Pooled it
- Omics-guided engineering of CHO cells reveals host targets to support AAV production.Molecular therapy. Advances · 2026Article
- Expression and immunoassay application of full-length recombinant antibody recognizing chlorantraniliprole using Pichia pastoris expression system.Crop health · 2026Article
- Lipid-Based Delivery Systems for Therapeutic Glycoproteins: Current Advances, Challenges, and Future Perspectives.Pharmaceutics · 2026Review
- UniSePT: an engineered broadly applicable Unique Secretory signal PepTide for high-yield biotherapeutic production in mammalian cell-based expression systems.Journal of biological engineering · 2026Article
- Advancements in photobiomodulation for generating functional beta cells from adipose derived stem cells in 3D culture: a comprehensive review.Stem cell research & therapy · 2025Review
- Preclinical Assessment of Living Therapeutic Materials: State-of-Art and Challenges.ACS biomaterials science & engineering · 2025Review
- Purification of Human Immunoglobulin G with Bathophenanthroline-ZnAntibodies (Basel, Switzerland) · 2025Article
- The SARS-CoV-2 Spike Protein Receptor-Binding Domain Expressed in Rice Callus Features a Homogeneous Mix of Complex-Type Glycans.International journal of molecular sciences · 2024Article
- New Frontiers in Three-Dimensional Culture Platforms to Improve Diabetes Research.Pharmaceutics · 2023Review
- Article
- Progress of Transposon Vector System for Production of Recombinant Therapeutic Proteins in Mammalian Cells.Frontiers in bioengineering and biotechnology · 2022Review
- Mammalian Cell Culture as a Platform for Veterinary Vaccines.Methods in molecular biology (Clifton, N.J.) · 2022Article
- High Throughput miRNA Screening Identifies miR-574-3p Hyperproductive Effect in CHO Cells.Biomolecules · 2021Article
- The role of protein hydrolysates in prolonging viability and enhancing antibody production of CHO cells.Applied microbiology and biotechnology · 2021Article
- Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product.Communications biology · 2021Article
- Glycoengineering of Mammalian Expression Systems on a Cellular Level.Advances in biochemical engineering/biotechnology · 2021Article
- Structure, Function, and Therapeutic Use of IgM Antibodies.Antibodies (Basel, Switzerland) · 2020Review
- Effects of autophagy inducers on recombinant antibody production in insect cells.Cytotechnology · 2020Article
- Construction of an expression vector mediated by the dual promoter for prokaryotic and mammalian cell expression system.Molecular biology reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The demand for production of glycoproteins from mammalian cell culture continues with an increased number of approvals as biopharmaceuticals for the treatment of unmet medical needs. This is particularly the case for humanized monoclonal antibodies which are the largest and fastest growing class of therapeutic pharmaceuticals. This demand has fostered efforts to improve the efficiency of production as well as to address the quality of the final product. Chinese hamster ovary cells are the predominant hosts for stable transfection and high efficiency production on a large scale. Specific productivity of recombinant glycoproteins from these cells can be expected to be above 50 pg/cell/day giving rise to culture systems with titers of around 5 g/L if appropriate fed-batch systems are employed. Cell engineering can delay the onset of programmed cell death to ensure prolonged maintenance of productive viable cells. The clinical efficacy and quality of the final product can be improved by strategic metabolic engineering. The best example of this is the targeted production of afucosylated antibodies with enhanced antibody-dependent cell cytotoxicity, an important function for use in cancer therapies. The development of culture media from non-animal sources continues and is important to ensure products of consistent quality and without the potential danger of contamination. Process efficiencies may also be improved by employing disposable bioreactors with the associated minimization of downtime. Finally, advances in downstream processing are needed to handle the increased supply of product from the bioreactor but maintaining the high purity demanded of these biopharmaceuticals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.